The antibody was purified by affinity chromatography and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice
Protect from prolonged exposure to light. Do not freeze.
Storage
4 °C
Storage Comment
The antibody solution should be stored undiluted between 2°C and 8°C.
Target
TREML2
(Triggering Receptor Expressed On Myeloid Cells-Like 2 (TREML2))
Alternative Name
TLT-2
Background
Trem-like transcript 2 protein (TLT2), also known as TREML2, is a 33 kD (unglycosylated) type I transmembrane protein with a single IgV domain containing two potential N-glycosylation sites, a serine/threonine-rich region with numerous predicted O-linked glycosylation sites, a single membrane-spanning region, and a short cytoplasmic tail. TLT2 is expressed on B lineage cells, macrophages, and neutrophils in bone marrow and periphery, and the expression level can be upregulated in response to inflammation. As a receptor, TLT2 likely plays a role in innate immunity. Recent studies have demonstrated that ligation of TLT2 inhibits the oxidative burst in neutrophils upon fMLP stimulation, indicating that TLT2 may function as an inhibitory receptor that attenuates activation of neutrophils and possibly macrophages. Recently, TLT-2 protein has been found on CD8+ T cells and is induced on activated CD4+ T cells.